Literature DB >> 3367385

212Bismuth linked to an antipancreatic carcinoma antibody: model for alpha-particle-emitter radioimmunotherapy.

S H Kurtzman1, A Russo, J B Mitchell, W DeGraff, W F Sindelar, M W Brechbiel, O A Gansow, A M Friedman, J J Hines, J Gamson.   

Abstract

For comparison of cytotoxicity from alpha-particle irradiation with that from conventional x-irradiation, 212Bi, an alpha-emitting radionuclide, was attached to a monoclonal antibody that recognizes a cell surface antigen on human pancreatic carcinoma cells. For a given level of survival, the 212Bi-antibody complex was found to be approximately 20 times more efficient in cell killing than x-irradiation and 5 times more cytotoxic when compared with the cytotoxicity of an antigen-negative cell line or an isotype-matched control antibody. High linear energy transfer radioimmunotherapy using alpha emitters linked to monoclonal antibodies may be useful in vivo and in vitro for selectively killing target cell populations, especially those resistant to other forms of treatment.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3367385     DOI: 10.1093/jnci/80.6.449

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  12 in total

1.  Multimodality therapy: potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease.

Authors:  Diane E Milenic; Kayhan Garmestani; Erik D Brady; Kwamena E Baidoo; Paul S Albert; Karen J Wong; Joseph Flynn; Martin W Brechbiel
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

Review 2.  Antibody mediated targeting of radioisotopes, drugs and toxins in diagnosis and treatment.

Authors:  C H Ford; V J Richardson; V S Reddy
Journal:  Indian J Pediatr       Date:  1990 Jan-Feb       Impact factor: 1.967

3.  Biological effect of lead-212 localized in the nucleus of mammalian cells: role of recoil energy in the radiotoxicity of internal alpha-particle emitters.

Authors:  M T Azure; R D Archer; K S Sastry; D V Rao; R W Howell
Journal:  Radiat Res       Date:  1994-11       Impact factor: 2.841

4.  Relative biological effectiveness of alpha-particle emitters in vivo at low doses.

Authors:  R W Howell; M T Azure; V R Narra; D V Rao
Journal:  Radiat Res       Date:  1994-03       Impact factor: 2.841

5.  (212)Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease.

Authors:  Kwon Joong Yong; Diane E Milenic; Kwamena E Baidoo; Martin W Brechbiel
Journal:  Mol Cancer Ther       Date:  2012-01-11       Impact factor: 6.261

6.  Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72.

Authors:  Diane E Milenic; Erik D Brady; Kayhan Garmestani; Paul S Albert; Alia Abdulla; Martin W Brechbiel
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

Review 7.  Targeted radionuclide therapies for pancreatic cancer.

Authors:  M Shah; R Da Silva; C Gravekamp; S K Libutti; T Abraham; E Dadachova
Journal:  Cancer Gene Ther       Date:  2015-07-31       Impact factor: 5.987

Review 8.  Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight".

Authors:  Romain Eychenne; Michel Chérel; Férid Haddad; François Guérard; Jean-François Gestin
Journal:  Pharmaceutics       Date:  2021-06-18       Impact factor: 6.321

Review 9.  Targeted and Nontargeted α-Particle Therapies.

Authors:  Michael R McDevitt; George Sgouros; Stavroula Sofou
Journal:  Annu Rev Biomed Eng       Date:  2018-01-18       Impact factor: 9.590

10.  Analysis of the therapeutic gain in the treatment of human osteosarcoma microcolonies in vitro with 211At-labelled monoclonal antibody.

Authors:  R H Larsen; O S Bruland; P Hoff; J Alstad; E K Rofstad
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.